Mobile

A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...

Mise à jour : Il y a 5 ans
Référence : EUCTR2009-016604-23

A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patients with Type 2 Diabetes treated with differing baseline diabetes therapies

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate canakinumab effects on change from baseline of meal challenge derived insulin secretion rate relative to glucose 0-2 hours (Φd), at 4 weeks, on the following populations: a. patients with T2DM pre-treated and continuing on stable metformin monotherapy b. patients with T2DM pre-treated and continuing on a stable metformin dose in combination with a sulfonylurea c. metformin in combination with a sulfonylurea and a thiazolidinedione d. treatment with at least two insulin injections a day with or without metformin e. in patients with impaired glucose tolerance (IGT)

Critère d'inclusion

  • Impaired Glucose Tolerance - Type 2 Diabetes

Liens